BioCryst Pharmaceuticals BCRX Repayment Of Royalty Financing Liabilities, Principal

Repayment Of Royalty Financing Liabilities, Principal at other companies

BridgeBio PharmaBBIO

$11.29M+7,742%

Syndax PharmaceuticalsSNDX

$343.91M+3.7%

AnaptysBio, Inc.ANAB

$12.81M-44.3%

RadNetRDNT

$9.95M+479%

Xenia Hotels & ResortsXHR

$1.04M+1.4%

Delek US HoldingsDK

$416.2M+41.4%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:RepaymentOfRoyaltyFinancingLiabilitiesPrincipal.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's repayment of royalty financing liabilities, principal.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's repayment of royalty financing liabilities, principal?: BioCryst Pharmaceuticals (BCRX) reported repayment of royalty financing liabilities, principal of $476K in Q1 2026.
What does repayment of royalty financing liabilities, principal mean?: Captures the principal portion of cash payments made to satisfy obligations under royalty-based financing agreements. This metric is critical for biotechnology companies that monetize future product revenue streams to fund current research and development activities.